Outcomes in patients with <i>BRAF</i> <sup>V600</sup> –mutated melanoma and brain metastases at baseline treated with dabrafenib plus trametinib
Massimo Aglietta(Candiolo Cancer Institute), Paola Queirolo, Maria Banzi(Azienda Ospedaliera S.Maria), Rossana Gueli, Massimo Guidoboni(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), Virginia Ferraresi(Cancer Institute (WIA)), Francesca Consoli(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Giovanni Lo Re(Centro di Riferimento Oncologico), Michele Guida(Istituto Tumori Bari), Giuseppe Tonini(Campus Bio Medico University Hospital), Paolo Fava, Roberta Depenni(University of Modena and Reggio Emilia), Riccardo Marconcini(Azienda Ospedaliera Universitaria Pisana), Alessandro Marco Minisini, Gaetana Rinaldi(AOL (United States)), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Ilaria Marcon(Ospedale di Circolo e Fondazione Macchi), Marco Tucci(Prostate Cancer UK)
Cited by 4
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k